<DOC>
	<DOCNO>NCT00313001</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The study compare A1C reduction achieve patient receive biphasic insulin aspart 70/30 twice daily patient receive exenatide twice daily . Patients enrol study insulin naive patient achieve glycemic control metformin sulfonylurea .</brief_summary>
	<brief_title>Effects Biphasic Insulin Aspart 70/30 vs. Exenatide Type 2 Diabetes Patients Not Reaching Blood Glucose Targets Metformin Sulfonylurea .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes HbA1C : At least 8 % Patients never treat insulin Current therapy metformin sulfonylurea . History recurrent , severe hypoglycemia Hepatic insufficiency : ALT , AST alkaline phosphatase &gt; 2.5 time upper limit laboratory 's normal Renal insufficiency : serum creatinine &gt; 1.3 mg/dL ( male ) &gt; 1.2 mg/dL ( female ) Severe gastrointestinal disease , include gastroparesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>